2.62

2.78% -0.08

Rocket Pharmaceuticals Inc (RCKT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.70

Aprire:

$2.68

Volume 24 ore:

909.84K

Relative Volume:

0.19

Capitalizzazione di mercato:

$340.45M

Reddito:

Utile/perdita netta:

$-258.08M

Rapporto P/E:

-0.9527

EPS:

-2.75

Flusso di cassa netto:

$-202.32M

1 W Prestazione:

-8.85%

1M Prestazione:

-58.13%

6M Prestazione:

-77.03%

1 anno Prestazione:

-88.32%

Intervallo 1D:

$2.62

$2.73

Intervallo di 1 settimana:

$2.62

$2.96

Portata 52W:

$2.19

$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Nome

Rocket Pharmaceuticals Inc

Settore

Healthcare (1174)

Industria

Biotechnology (662)

Telefono

646-440-9100

Indirizzo

350 FIFTH AVENUE, NEW YORK, NY

Dipendente

299

Cinguettio

@rocketpharma

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

RCKT's Discussions on Twitter

Confronta RCKT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RCKT Rocket Pharmaceuticals Inc	2.625	340.45M	0	-258.08M	-202.32M	-2.75
VRTX Vertex Pharmaceuticals Inc	440.88	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	511.89	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	309.67	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	536.66	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.38	28.51B	3.81B	-644.79M	-669.77M	-6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-30	Downgrade	Evercore ISI	Outperform → In-line
2025-05-28	Downgrade	Goldman	Neutral → Sell
2025-05-28	Downgrade	JP Morgan	Overweight → Neutral
2025-05-28	Downgrade	Jefferies	Buy → Hold
2025-05-28	Downgrade	Leerink Partners	Outperform → Market Perform
2025-05-28	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-05-27	Downgrade	Needham	Buy → Hold
2025-05-27	Downgrade	TD Cowen	Buy → Hold
2025-03-12	Iniziato	BMO Capital Markets	Outperform
2024-12-30	Iniziato	Wedbush	Outperform
2024-12-18	Iniziato	Jefferies	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-04-02	Iniziato	Goldman	Neutral
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-02-01	Iniziato	Morgan Stanley	Overweight
2022-11-08	Iniziato	Canaccord Genuity	Buy
2022-11-01	Iniziato	BTIG Research	Buy
2022-07-08	Iniziato	Raymond James	Outperform
2021-10-20	Ripresa	Cowen	Outperform
2021-03-02	Iniziato	Stifel	Buy
2021-02-18	Iniziato	Needham	Buy
2020-12-16	Iniziato	UBS	Buy
2020-12-08	Downgrade	Oppenheimer	Outperform → Perform
2020-07-02	Iniziato	JP Morgan	Overweight
2020-06-25	Ripresa	BofA/Merrill	Buy
2020-06-01	Ripresa	Oppenheimer	Outperform
2019-11-06	Iniziato	Chardan Capital Markets	Buy
2019-09-26	Iniziato	Piper Jaffray	Overweight
2019-04-23	Iniziato	Robert W. Baird	Outperform
2019-03-15	Iniziato	BofA/Merrill	Buy
2019-02-05	Iniziato	Oppenheimer	Outperform
2018-09-13	Iniziato	Ladenburg Thalmann	Buy
2018-07-10	Iniziato	William Blair	Outperform

Mostra tutto

Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie

Jun 18, 2025

Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com

Jun 18, 2025

Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga

Jun 18, 2025

Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025

RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Jun 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent

Jun 18, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World

Jun 18, 2025

Jun 17, 2025

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Jun 17, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus

Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire

Jun 17, 2025

UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener

Jun 17, 2025

UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus

Jun 17, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire

Jun 17, 2025

Jun 16, 2025

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph

Jun 16, 2025

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus

Jun 16, 2025

Jun 15, 2025

Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire

Jun 15, 2025

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire

Jun 15, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com

Jun 15, 2025

RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025

RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire

Jun 15, 2025

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia

Jun 14, 2025

RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Jun 14, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 13, 2025

ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView

Jun 13, 2025

RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 13, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire

Jun 13, 2025

Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire

Jun 13, 2025

RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire

Jun 13, 2025